Skip to main content

Table 2 Genotype frequency distribution and association with stroke outcome at three months for MMP-2 SNPs.

From: Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke

  

Whole sample*

Ischemic subset†

  

Genotype frequency

  

Genotype frequency

  

SNP

Genotype

Good recovery, n (%)

Poor recovery, n (%)

OR [95%CI]

P

Good recovery, n (%)

Poor recovery, n (%)

OR [95%CI]

P

rs243866

         
 

G/G

142 (67.6)

117 (57.9)

1.67 [1.10-2.52]

0.0143

125 (67.6)

83 (56.8)

1.78 [1.13-2.80]

0.0128

 

A/G

66 (31.4)

76 (37.6)

  

59 (31.9)

55 (37.7)

  
 

A/A

2 (1.0)

9 (4.5)

  

1 (0.5)

8 (5.5)

  

rs243865

         
 

C/C

141 (67.8)

117 (57.9)

1.65 [1.09-2.50]

0.0162

124 (67.8)

83 (56.8)

1.76 [1.12-2.78]

0.0143

 

C/T

65 (31.2)

76 (37.6)

  

58 (31.7)

55 (37.7)

  
 

T/T

2 (1.0)

9 (4.5)

  

1 (0.5)

8 (5.5)

  

rs857403

         
 

A/A

124 (59.3)

138 (68.3)

0.71 [0.48-1.06]

0.0909

105 (57.1)

103 (70.5)

0.62 [0.40-0.97]

0.0349

 

T/A

75 (35.9)

56 (27.7)

  

70 (38)

37 (25.3)

  
 

T/T

10 (4.8)

8 (4.0)

  

9 (4.9)

6 (4.1)

  

rs1477017

         
 

A/A

100 (47.6)

81 (40.1)

1.42 [1.01-2.00]

0.0415

86 (46.5)

55 (37.7)

1.51 [1.04-2.20]

0.0306

 

G/A

91 (43.3)

98 (48.5)

  

82 (44.3)

72 (49.3)

  
 

G/G

19 (9.0)

23 (11.4)

  

17 (9.2)

19 (13)

  

rs17301608

         
 

C/C

94 (45.0)

75 (37.3)

1.40 [1.00-1.95]

0.0510

80 (43.5)

50 (34.5)

1.47 [1.01-2.12]

0.0412

 

C/T

94 (45.0)

100 (49.8)

  

85 (46.2)

73 (50.3)

  
 

T/T

21 (10.0)

26 (12.9)

  

19 (10.3)

22 (15.2)

  

rs1053605

         
 

C/C

188 (89.5)

170 (84.2)

2.02 [1.09-3.75]

0.0227

166 (89.7)

127 (87.0)

1.82 [0.93-3.58]

0.0817

 

C/T

22 (10.5)

28 (13.9)

  

19 (10.3)

16 (11.0)

  
 

T/T

0 (0.0)

4 (2.0)

  

0 (0.0)

3 (2.0)

  

rs2241145

         
 

G/G

79 (37.8)

56 (27.9)

1.66 [1.20-2.30]

0.0021 ‡

68 (37.0)

39 (26.9)

1.67 [1.17-2.40]

0.0044

 

G/C

100 (47.8)

101 (50.2)

  

88 (47.8)

72 (49.7)

  
 

C/C

30 (14.4)

44 (21.9)

  

28 (15.2)

34 (23.4)

  

rs243849

         
 

C/C

131 (62.7)

143 (71.5)

0.70 [0.46-1.07]

0.0948

112 (60.9)

108 (75)

0.59 [0.36-0.96]

0.0314

 

T/C

70 (33.5)

52 (26.0)

  

65 (35.3)

33 (22.9)

  
 

T/T

8 (3.8)

5 (2.5)

  

7 (3.8)

3 (2.1)

  

rs183112

         
 

G/G

134 (64.1)

145 (72.9)

0.66 [0.43-1.03]

0.0669

115 (62.5)

110 (76.9)

0.54 [0.32-0.90]

0.0162

 

A/G

70 (33.5)

51 (25.6)

  

65 (35.3)

32 (22.4)

  
 

A/A

5 (2.4)

3 (1.5)

  

4 (2.2)

1 (0.7)

  

rs1992116

         
 

G/G

87 (41.6)

65 (32.3)

1.67 [1.20-2.31]

0.0018 ‡

76 (41.3)

48 (33.1)

1.68 [1.17-2.42]

0.0042

 

A/G

97 (46.4)

94 (46.8)

  

86 (46.7)

67 (46.2)

  
 

A/A

25 (12.0)

42 (20.9)

  

22 (12.0)

30 (20.7)

  
  1. 95%CI - 95% Confidence Interval.
  2. *OR [95%CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, type of stroke, and occurrence of aphasia, paresis, consciousness disturbance and complications during hospitalization).
  3. †OR [95%CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, and occurrence of aphasia, paresis, consciousness disturbance and complications during hospitalization).
  4. ‡Significant result after Bonferroni correction.
  5. Results were adjusted for significant covariates; Odds Ratio (OR)>1 indicates increased probability of poor recovery for the carriers of the minor allele; only associated SNPs are shown.
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us